Serum vaspin levels are positively associated with carotid atherosclerosis in a general population

Atherosclerosis

Volumn 233, Issue 1, 2014, Pages 248-252

  Esaki, Eishi ^a   Adachi, Hisashi ^a   Hirai, Yuji ^a   Yamagishi, Sho ichi ^a   Kakuma, Tatsuyuki ^a   Enomoto, Mika ^a   Fukami, Ako ^a   Kumagai, Eita ^a   Ohbu, Kyoko ^a   Obuchi, Aya ^a   Yoshimura, Ayako ^a   Nakamura, Sachiko ^a   Nohara, Yume ^a   Fujiyama, Tomoki ^a   Fukumoto, Yoshihiro ^a   Imaizumi, Tsutomu ^b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

Author keywords

Carotid atherosclerosis; Epidemiology; Insulin resistance; Vaspin

Indexed keywords

CAROTID ATHEROSCLEROSIS; EPIDEMIOLOGY; INSULIN RESISTANCE; VASPIN;

ADULT; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; FEMALE; HOMEOSTASIS; HUMANS; INSULIN RESISTANCE; JAPAN; MALE; MODELS, BIOLOGICAL; SERPINS;

EID: 84893922213     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.12.040     Document Type: Article

References (33)

1. Hida K., Wada J., Zhang H., et al. Identification of genes specifically expressed in the accumulated visceral adipose tissue of OLETF rats. JLipid Res 2000, 41:1615-1622.
2. Hida K., Wada J., Eguchi J., et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005, 102:10610-10615.
3. Shaker O.G., Sadik N.A. Vaspin gene in rat adipose tissue: relation to obesity-induced insulin resistance. Mol Cell Biochem 2013, 373:229-239.
4. Rabe K., Lehrke M., Parhofer K.G., Broedl U. Adipokines and insulin resistance. Mol Med 2008, 14:741-751.
5. Wada J. Vaspin: a novel serpin with insulin-sensitizing effects. Expert Opin Investig Drugs 2008, 17:327-333.
6. Li K., Li L., Yang M., et al. Short-term continuous subcutaneous insulin infusion decreases the plasma vaspin levels in patients with type 2 diabetes mellitus concomitant with improvement in insulin sensitivity. Eur J Endocrinol 2011, 164:905-910.
7. Li Q., Chen R., Moriya J., et al. Anovel adipocytokine, visceral adipose tissue-derived serine protease inhibitor (vaspin), and obesity. JInt Med Res 2008, 36:625-629.
8. Blüher M. Vaspin in obesity and diabetes: pathophysiological and clinical significance. Endocrine 2012, 41:176-182.
9. Youn B.S., Kloting N., Kratzsch J., et al. Serum vaspin concentrations in human obesity and type 2 diabetes. Diabetes 2008, 57:372-377.
10. Golpaie A., Tajik N., Masoudkabir F., et al. Short-term effect of weight loss through restrictive bariatric surgery on serum levels of vaspin in morbidly obese subjects. Eur Cytokine Netw 2011, 22:181-186.
11. Handisurya A., Riedl M., Vila G., et al. Serum vaspin concentrations in relation to insulin sensitivity following RYGB-induced weight loss. Obes Surg 2010, 20:198-203.
12. Jung C.H., Lee W.J., Hwang J.Y., et al. Vaspin increased nitric oxide bioavailability through the reduction of asymmetric dimethylarginine in vascular endothelial cells. PLoS ONE 2012, 7:1-9.
13. Nakatsuka A., Wada J., Iseda I., et al. Visceral adipose tissue-derived serine proteinase inhibitor inhibits apoptosis of endothelial cells as a ligand for the cell-surface GPR78/voltage-dependent anion channel complex. Circ Res 2013, 112:771-780.
14. Matsuo S., Imai E., Horio M., et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009, 53:982-992.
15. Pignoli P., Tremoli E., Poli A., Oreste P., Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurements with ultrasound imaging. Circulation 1986, 74:1399-1406.
16. Yamasaki Y., Kodama M., Nishizawa H., et al. Carotid intima-media thickness in Japanese type 2 diabetic subjects. Diabetes Care 2000, 23:1310-1315.
17. Teshigawara S., Wada J., Hida K., et al. Serum vaspin concentrations are closely related to insulin resistance, and rs77060950 at SERPINA12 genetically defines distinct group with higher serum levels in Japanese population. JClin Endocrinol Metab 2012, 97:E1202-E1207.
18. Cho J.K., Han T.K., Kang H.S. Combined effect of body mass index and cardio/respiratory fitness on serum vaspin concentrations in Korean young men. Eur J Appl Physiol 2010, 108:347-353.
19. Lee M.K., Jekal Y., Im J.A., et al. Reduced serum vaspin concentrations in obese children following short-term intensive lifestyle modification. Clin Chim Acta 2010, 411:381-385.
20. Suleymanoglu S., Tascilar E., Pirgon O., Tapan S., Meral C., Abaci A. Vaspin and its correlation with insulin sensitivity indices in obese children. Diabetes Res Clin Pract 2009, 84:325-328.
21. Koiou E., Tziomalos K., Dinas K., et al. The effect of weight loss and treatment with metformin on serum vaspin levels in women polycystic ovary syndrome. Endocrinol J 2011, 58:237-246.
22. Tan B.K., Heutling D., Chen J., et al. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008, 57:1501-1507.
23. Gonzalez C.R., Caminos J.E., Vazquez M.J., et al. Regulation of vaspin by nutritional status, metformin, gender and pituitary factors in rat white adipose tissue. JPhysiol 2009, 587:3741-3750.
24. Al-Azzam S.I., Alzoubi K.H., Abeeleh J.A., Mhaidat N.M., Abu-Abeeleh M. Effect of statin therapy on vaspin levels in type 2 diabetic patients. Clin Pharmacol 2013, 5:33-38.
25. Nakatsuka A., Wada J., Iseda I., et al. Vaspin is an adipokine ameliorating ER stress in obesity as a ligand for cell-surface GRP78/MTJ-1 complex. Diabetes 2012, 61:2823-2832.
26. Gulcelik N.E., Karakaya J., Gedik A., Usman A., Gurlek A. Serum vaspin levels in type 2 diabetic women in relation to microvascular complications. Eur J Endocrinol 2009, 160:65-70.
27. Cura H.S., Özdemir H.H., Demir C.F., Bulut S., Ilhan N., Inci M.F. Investigation of vaspin level in patients with acute ischemic stroke. JStroke Cerebrovasc Dis 2013, in press.
28. Aust G., Richter O., Rohm S., et al. Vaspin serum concentrations in patients with carotid stenosis. Atherosclerosis 2009, 204:262-266.
29. Choi S.H., Kwak S.H., Lee Y., et al. Plasma vaspin concentrations are elevated in metabolic syndrome in men and are correlated with coronary atherosclerosis in women. Clin Endocrinol 2011, 75:628-635.
30. Jung C.H., Lee W.J., Hwang J.Y., et al. Vaspin protects vascular endothelial cells against free fatty acid-induced apoptosis through a phosphatidylinositol 3-kinase/Akt pathway. Biochem Biophys Res Commun 2011, 413:264-269.
31. Phalitakul S., Okada M., Hara Y., Yamawaki H. Anovel adipocytokine, vaspin inhibits platelet-derived growth factor-BB-induced migration of vascular smooth muscle cells. Biochem Biophys Res Commun 2012, 423:844-849.
32. Inoue J., Wada J., Teshigawara S., et al. The serum vaspin levels are reducedin Japanese chronic hemodialysis patients. BMC Nephrol 2012, 13:163-167.
33. Seeger J., Ziegelmeier M., Bachmann A., et al. Serum levels of the adipokine vaspin in relation to metabolic and renal parameters. JClin Endocrinol Metab 2008, 93:247-251.